Technical analysis of Incyte Corporation (INCY): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive a...
Price Performance
| 1 month | +1.04% |
| 3 months | +27.01% |
| Year-to-date | +26.30% |
| 1 year | +47.11% |
| 3 years | +109.63% |
| 5 years | +64.17% |
52-Week Range
| 52-week High | $132.60 |
| 52-week Low | $81.09 |
| Avg Volume (90d) | 1.7M |
Technical Indicators
| SMA 50 | $121.96 |
| SMA 200 | $105.41 |
| Beta | 0.86 |
| 30-day Volatility (annualised) | 24.7% |
| Price vs SMA 50 | +2.3% |
| Price vs SMA 200 | +18.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $93.48 | |
| 2025-11 | $104.46 | +11.7% |
| 2025-12 | $98.77 | -5.4% |
| 2026-01 | $100.07 | +1.3% |
| 2026-02 | $101.27 | +1.2% |
| 2026-03 | $94.12 | -7.1% |
| 2026-04 | $95.27 | +1.2% |
| 2026-05 | $96.74 | +1.5% |
| 2026-06 | $113.36 | +17.2% |
| 2026-07 | $119.52 | +5.4% |
| 2026-08 | $123.22 | +3.1% |
| 2026-09 | $124.75 | +1.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $121.47 |
| Market Cap | $24.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 15.34 |
| Price / Book | 3.94 |
| EV / EBITDA | 9.23 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 4.66 |
| Piotroski F-Score | 8 |
| Altman Z-Score | 8.44 |